[{"id":"fb860809-ebea-4c05-af96-bfe14c08cdf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02932956","created_at":"2021-03-12T11:53:07.388Z","updated_at":"2024-07-02T16:35:46.433Z","phase":"Phase 1","brief_title":"Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)","source_id_and_acronym":"NCT02932956","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GAP T cells • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/17/2018","start_date":" 12/17/2018","primary_txt":" Primary completion: 09/27/2021","primary_completion_date":" 09/27/2021","study_txt":" Completion: 02/01/2037","study_completion_date":" 02/01/2037","last_update_posted":"2023-06-06"}]